Ibrexafungerp, a Novel Oral Triterpenoid Antifungal in Development: Overview of Antifungal Activity Against Candida glabrata

Gamal, Ahmed; Chu, Sherman; McCormick, Thomas S.; Borroto-Esoda, Katyna; Angulo, David; Ghannoum, Mahmoud A.

doi:10.3389/fcimb.2021.642358

Cited by 58Antifungal resistance and susceptibilityFungal Plant Pathogen ControlFungal Infections and Studies

Ibrexafungerp, a Novel Oral Triterpenoid Antifungal in Development: Overview of Antifungal Activity Against Candida glabrata

Open access

Gamal, Ahmed, Chu, Sherman, McCormick, Thomas S., Borroto-Esoda, Katyna, Angulo, David, Ghannoum, Mahmoud A.·2021·Frontiers in Cellular and Infection Microbiology

DOI 10.3389/fcimb.2021.642358PMC PMC8006402

Open this paper in CoChat — free account Open PDF

Abstract

Systemic infections caused by Candida species are an important cause of morbidity and mortality among immunocompromised and non-immunocompromised patients. In particular, Candida glabrata is an emerging species within the Candida family that causes infections ranging from superficial to life-threatening systemic disease. Echinocandins and azoles are typically the first-line therapies used to treat infections caused by C. glabrata , however, there is an increasing prevalence of resistance to these antifungal agents in patients. Thus, a need exists for novel therapies that demonstrate high efficacy against C. glabrata . Ibrexafungerp is a first-in-class glucan synthase inhibitor with oral availability developed to address this increasing antifungal resistance. Ibrexafungerp demonstrates broad in vitro activity against wild-type, azole-resistant, and echinocandin-resistant C. glabrata species. Furthermore, ibrexafungerp has shown efficacy in low pH environments, which suggests its potential effectiveness in treating vulvovaginal candidiasis. Additional preclinical and clinical studies are needed to further examine the mechanism(s) of ibrexafungerp, including acting as a promising new agent for treating C. glabrata infections.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.3389/fcimb.2021.642358

Cites

72 of 73 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Ibrexafungerp is an oral 1,3-β-D-glucan synthase inhibitor that is FDA approved to treat acute VVC.
“Ibrexafungerp (formerly SCY-078; SCYNEXIS Inc., Jersey City, New Jersey) is an oral 1,3-β-D-glucan synthase inhibitor 32 that is FDA approved to treat acute VVC. 33”
From Clinical challenges in diagnosis and treatment of recurrent vulvovaginal candidiasis (2022) · cites this paper as [32]
Oteseconazole or ibrexafungerp seem to be effective in relapses of VVC.
“Although oteseconazole or ibrexafungerp seem to be effective in relapses, more clinical trials or treatment regimens for these drugs still need to be conducted.”
From Treatment of Vulvovaginal Candidiasis—An Overview of Guidelines and the Latest Treatment Methods (2023) · cites this paper as [75]
Ibrexafungerp is an oral β-1,3-D-glucan synthase inhibitor (GSI) of the enfumafungin-derived triterpenoid class of antifungals (echinocandins).
“For instance, ibrexafungerp is an oral β-1,3-D-glucan synthase inhibitor (GSI) of the enfumafungin-derived triterpenoid class of antifungals (echinocandins) (Gamal et al., 2021).”
From Management of recurrent vulvovaginal candidosis: Narrative review of the literature and European expert panel opinion (2022) · cites this paper as Gamal et al., 2021
Preclinical studies have shown equal or superior in vitro activity compared with echinocandins, such as caspofungin and micafungin, against both wild-type and echinocandin-resistant C. glabrata isolates.
“Preclinical studies have shown equal or superior in vitro activity compared with echinocandins, such as caspofungin and micafungin, against both wild-type and echinocandin-resistant C. glabrata isolates (Gamal et al., 2021).”
From Management of recurrent vulvovaginal candidosis: Narrative review of the literature and European expert panel opinion (2022) · cites this paper as Gamal et al., 2021

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Epidemiology of Invasive Candidiasis: a Persistent Public Health Problem
Pfaller, M. A., & Diekema, D. J. (2007) · Clinical Microbiology Reviews · doi:10.1128/cmr.00029-06 · Cited by 4,174 · cited 1× · see citing works
“glabrata resistance to currently available antifungals is increasing and the emergence of multidrug resistance threatens the effectiveness of both azoles and echinocandins (Pfaller and Diekema, 2007).”
Background
Antifungal Agents: Mode of Action, Mechanisms of Resistance, and Correlation of These Mechanisms with Bacterial Resistance
Ghannoum, M. A., & Rice, L. B. (1999) · Clinical Microbiology Reviews · doi:10.1128/cmr.12.4.501 · Cited by 1,788 · see citing works
Self-citation
Vulvovaginal candidosis
Sobel, J. D. (2007) · The Lancet · doi:10.1016/s0140-6736(07)60917-9 · Cited by 1,270 · see citing works
Candida species: current epidemiology, pathogenicity, biofilm formation, natural antifungal products and new therapeutic options
Sardi, J. C. O., Scorzoni, L., Bernardi, T., Fusco-Almeida, A. M., & Mendes Giannini, M. J. S. (2013) · Journal of Medical Microbiology · doi:10.1099/jmm.0.045054-0 · Cited by 1,184 · see citing works
Candida glabrata : Review of Epidemiology, Pathogenesis, and Clinical Disease with Comparison to C. albicans
Fidel, P. L., Vazquez, J. A., & Sobel, J. D. (1999) · Clinical Microbiology Reviews · doi:10.1128/cmr.12.1.80 · Cited by 953 · see citing works
Increasing Echinocandin Resistance in Candida glabrata: Clinical Failure Correlates With Presence of FKS Mutations and Elevated Minimum Inhibitory Concentrations
Alexander, B. D., Johnson, M. D., Pfeiffer, C. D., Jiménez-Ortigosa, C., Catania, J., Booker, R., Castanheira, M., Messer, S. A., Perlin, D. S., & Pfaller, M. A. (2013) · Clinical Infectious Diseases · doi:10.1093/cid/cit136 · Cited by 778 · see citing works
Multidrug-Resistant Candida: Epidemiology, Molecular Mechanisms, and Treatment
Arendrup, M. C., & Patterson, T. F. (2017) · The Journal of Infectious Diseases · doi:10.1093/infdis/jix131 · Cited by 707 · see citing works
Changing epidemiology of systemic fungal infections
Richardson, M., & Lass-Flörl, C. (2008) · Clinical Microbiology and Infection · doi:10.1111/j.1469-0691.2008.01978.x · Cited by 524 · see citing works
EUCAST technical note on the EUCAST definitive document EDef 7.2: method for the determination of broth dilution minimum inhibitory concentrations of antifungal agents for yeasts EDef 7.2 (EUCAST-AFST)
Arendrup, M. C., Cuenca-Estrella, M., Lass-Flörl, C., & Hope, W. (2012) · Clinical Microbiology and Infection · doi:10.1111/j.1469-0691.2012.03880.x · Cited by 451 · see citing works
Antifungal Susceptibilities of Candida Species Causing Vulvovaginitis and Epidemiology of Recurrent Cases
Richter, S. S., Galask, R. P., Messer, S. A., Hollis, R. J., Diekema, D. J., & Pfaller, M. A. (2005) · Journal of Clinical Microbiology · doi:10.1128/jcm.43.5.2155-2162.2005 · Cited by 435 · see citing works
Emerging Threats in Antifungal-Resistant Fungal Pathogens
Sanglard, D. (2016) · Frontiers in Medicine · doi:10.3389/fmed.2016.00011 · Cited by 420 · see citing works
The emerging pathogen Candida auris: growth phenotype, virulence factors, activity of antifungals, and effect of SCY-078, a novel glucan synthesis inhibitor, on growth morphology and biofilm formation
Larkin, E., Hager, C., Chandra, J., Mukherjee, P. K., Retuerto, M., Salem, I., Long, L., Isham, N., Kovanda, L., Borroto-Esoda, K., et al. (2017) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02396-16 · Cited by 395 · see citing works
Self-citation
Epidemiology and outcomes of candidemia in 3648 patients: data from the Prospective Antifungal Therapy (PATH Alliance®) registry, 2004–2008
Pfaller, M. A., Neofytos, D., Diekema, D. J., Azie, N. E., Meier‐Kriesche, H., Quan, S.-P., & Horn, D. (2012) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/j.diagmicrobio.2012.10.003 · Cited by 391 · see citing works
Frequency of decreased susceptibility and resistance to echinocandins among fluconazole-resistant bloodstream isolates of Candida glabrata
Pfaller, M. A., Castanheira, M., Lockhart, S. R., Ahlquist, A. M., Messer, S. A., & Jones, R. N. (2012) · Journal of Clinical Microbiology · doi:10.1128/jcm.06112-11 · Cited by 377 · see citing works
Evaluation of Vaginal Complaints
Anderson, M. (2004) · JAMA · doi:10.1001/jama.291.11.1368 · Cited by 375 · see citing works
The changing face of epidemiology of invasive fungal disease in Europe
Lass‐Flörl, C. (2009) · Mycoses · doi:10.1111/j.1439-0507.2009.01691.x · Cited by 365 · see citing works
Epidemiological trends in nosocomial candidemia in intensive care
Bassetti, M., Righi, E., Costa, A., Fasce, R., Molinari, M. P., Rosso, R., Pallavicini, F. B., & Viscoli, C. (2006) · BMC Infectious Diseases · doi:10.1186/1471-2334-6-21 · Cited by 332 · see citing works
Species identification and antifungal susceptibility testing of Candida bloodstream isolates from population-based surveillance studies in two U.S. cities from 2008 to 2011.
Lockhart, S. R., Iqbal, N., Cleveland, A. A., Farley, M. M., Harrison, L. H., Bolden, C. B., Baughman, W., Stein, B., Hollick, R., Park, B. J., et al. (2012) · Journal of Clinical Microbiology · doi:10.1128/jcm.01283-12 · Cited by 299 · see citing works
Prevalent mutator genotype identified in fungal pathogen Candida glabrata promotes multi-drug resistance.
Healey, K. R., Zhao, Y., Perez, W. B., Lockhart, S. R., Sobel, J. D., Farmakiotis, D., Kontoyiannis, D. P., Sanglard, D., Taj-Aldeen, S. J., Alexander, B. D., et al. (2016) · Nature Communications · doi:10.1038/ncomms11128 · Cited by 276 · see citing works
A yeast by any other name: Candida glabrata and its interaction with the host
Kaur, R., Domergue, R., Zupancic, M. L., & Cormack, B. P. (2005) · Current Opinion in Microbiology · doi:10.1016/j.mib.2005.06.012 · Cited by 271 · see citing works
Role of FKS mutations in Candida glabrata: MIC values, echinocandin resistance, and multidrug resistance
Pham, C. D., Iqbal, N., Bolden, C. B., Kuykendall, R. J., Harrison, L. H., Farley, M. M., Schaffner, W., Beldavs, Z. G., Chiller, T. M., Park, B. J., et al. (2014) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.03255-14 · Cited by 231 · see citing works
Population-Based Active Surveillance for Culture-Confirmed Candidemia — Four Sites, United States, 2012–2016
Toda, M., Williams, S. R., Berkow, E. L., Farley, M. M., Harrison, L. H., Bonner, L., Marceaux, K. M., Hollick, R., Zhang, A. Y., Schaffner, W., et al. (2019) · MMWR Surveillance Summaries · doi:10.15585/mmwr.ss6808a1 · Cited by 198 · cited 4× · see citing works
“Interestingly, these mutations were more frequent among fluconazole-resistant and MDR C. glabrata isolates (Healey et al., 2016).”
BackgroundResultInfluential
An Update on the Roles of Non-albicans Candida Species in Vulvovaginitis
Makanjuola, O., Bongomin, F., & Fayemiwo, S. (2018) · Journal of Fungi · doi:10.3390/jof4040121 · Cited by 182 · see citing works
An epidemiological survey of vulvovaginal candidiasis in Italy
Corsello, S., Spinillo, A., Osnengo, G., Penna, C., Guaschino, S., Beltrame, A., Blasi, N., & Festa, A. (2003) · European Journal of Obstetrics & Gynecology and Reproductive Biology · doi:10.1016/s0301-2115(03)00096-4 · Cited by 181 · see citing works
FKS Mutant Candida glabrata: Risk Factors and Outcomes in Patients With Candidemia
Beyda, N. D., John, J., Kilic, A., Alam, M. J., Lasco, T. M., & Garey, K. W. (2014) · Clinical Infectious Diseases · doi:10.1093/cid/ciu407 · Cited by 174 · see citing works
Prevalence of Candida species and potential risk factors for vulvovaginal candidiasis in Aligarh, India
Ahmad, A., & Khan, A. U. (2009) · European Journal of Obstetrics & Gynecology and Reproductive Biology · doi:10.1016/j.ejogrb.2008.12.020 · Cited by 154 · see citing works
Prevalence of clinical vaginal candidiasis in a university hospital and possible risk factors
Grigoriou, O., Baka, S. G., Makrakis, E., Hassiakos, D., Kaparos, G., & Kouskouni, E. E. (2005) · European Journal of Obstetrics & Gynecology and Reproductive Biology · doi:10.1016/j.ejogrb.2005.09.015 · Cited by 152 · see citing works
Drug-ResistantCandida glabrataInfection in Cancer Patients
Farmakiotis, D., Tarrand, J. J., & Kontoyiannis, D. P. (2014) · Emerging Infectious Diseases · doi:10.3201/eid2011.140685 · Cited by 152 · see citing works
Species-specific Prevalence of Vaginal Candidiasis Among Patients with Diabetes Mellitus and its Relation to their Glycaemic Status
Goswami, R., Dadhwal, V., Tejaswi, S., Datta, K., Paul, A., Haricharan, R. N., Banerjee, U., & Kochupillai, N. (2000) · Journal of Infection · doi:10.1053/jinf.2000.0723 · Cited by 146 · see citing works
Recent experience with fungaemia: change in species distribution and azole resistance
Chakrabarti, A., Chatterjee, S. S., Rao, K. L. N., Zameer, M., Rudramurthy, S. M., Singhi, S. C., Singh, R., & Varma, S. C. (2009) · Scandinavian Journal of Infectious Diseases · doi:10.1080/00365540902777105 · Cited by 132 · see citing works
Vulvovaginal carriage of yeasts other than Candida albicans
Holland, J. (2003) · Sexually Transmitted Infections · doi:10.1136/sti.79.3.249 · Cited by 132 · see citing works
Candida and invasive candidiasis: back to basics
Lim, C. S. Y., Rosli, R., Seow, H. F., & Chong, P. P. (2011) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/s10096-011-1273-3 · Cited by 128 · see citing works
Enfumafungin Derivative MK-3118 Shows Increased In Vitro Potency against Clinical Echinocandin-Resistant Candida Species and Aspergillus Species Isolates
Jiménez‐Ortigosa, C., Paderu, P., Motyl, M. R., & Perlin, D. S. (2013) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02145-13 · Cited by 122 · see citing works
Rapid Acquisition of Stable Azole Resistance by Candida glabrata Isolates Obtained before the Clinical Introduction of Fluconazole
Borst, A., Raimer, M. T., Warnock, D. W., Morrison, C. J., & Arthington, B. A. (2005) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.49.2.783-787.2005 · Cited by 107 · see citing works
In Vitro Activity of a Novel Glucan Synthase Inhibitor, SCY-078, against Clinical Isolates of Candida auris
Berkow, E. L., Angulo, D. A., & Lockhart, S. R. (2017) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00435-17 · Cited by 103 · see citing works
Self-citation
A 5‐year (2000–2004) epidemiological survey of Candida and non‐Candida yeast species causing vulvovaginal candidiasis in Graz, Austria
Paulitsch‐Fuchs, A. H., Weger, W., Ginter‐Hanselmayer, G., Marth, E., & Buzina, W. (2006) · Mycoses · doi:10.1111/j.1439-0507.2006.01284.x · Cited by 102 · see citing works
The distribution frequency of Candida species in the genitourinary tract among symptomatic individuals in Nigerian cities.
Okungbowa, F. I., Isikhuemhen, O. S., & Dede, A. P. O. (2003) · PubMed · Cited by 96 · see citing works
Pharmacodynamic Target Evaluation of a Novel Oral Glucan Synthase Inhibitor, SCY-078 (MK-3118), Using an In Vivo Murine Invasive Candidiasis Model
Lepak, A. J., Marchillo, K., & Andes, D. R. (2014) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.04445-14 · Cited by 95 · see citing works
Preclinical Pharmacokinetics and Pharmacodynamic Target of SCY-078, a First-in-Class Orally Active Antifungal Glucan Synthesis Inhibitor, in Murine Models of Disseminated Candidiasis
Wring, S. A., Randolph, R., Park, S., Abruzzo, G. K., Chen, Q., Flattery, A. M., Garrett, G. C., Peel, M. R., Outcalt, R. J., Powell, K. D., et al. (2017) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02068-16 · Cited by 94 · see citing works
Self-citation
Ibrexafungerp: A Novel Oral Triterpenoid Antifungal in Development for the Treatment of Candida auris Infections
Ghannoum, M. A., Arendrup, M. C., Chaturvedi, V. P., Lockhart, S. R., McCormick, T. S., Chaturvedi, S., Berkow, E. L., Juneja, D., Tarai, B., Azie, N. E., et al. (2020) · Antibiotics · doi:10.3390/antibiotics9090539 · Cited by 92 · see citing works
Self-citation
Prevalence & susceptibility to fluconazole of Candida species causing vulvovaginitis.
Mohanty, S., Xess, I., Hasan, F., Kapil, A., Mittal, S., & Tolosa, J. E. (2007) · PubMed · Cited by 91 · see citing works
Fluconazole and itraconazole susceptibility of vaginal yeast isolates from Slovakia
Sojakova, M., Liptajova, D., Borovský, M., & Šubík, J. (2004) · Mycopathologia · doi:10.1023/b:myco.0000020594.35357.b0 · Cited by 91 · see citing works
Ibrexafungerp: A novel oral glucan synthase inhibitor
Davis, M. R., Donnelley, M. A., & Thompson, G. R. (2020) · Medical Mycology · doi:10.1093/mmy/myz083 · Cited by 91 · see citing works
De Novo Acquisition of Resistance to SCY-078 in Candida glabrata Involves FKS Mutations That both Overlap and Are Distinct from Those Conferring Echinocandin Resistance
Jiménez-Ortigosa, C., Perez, W. B., Angulo, D., Borroto-Esoda, K., & Perlin, D. S. (2017) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00833-17 · Cited by 89 · see citing works
Self-citation
Differential activity of the oral glucan synthase inhibitor SCY-078 against wild-type and echinocandin-resistant strains of Candida species
Pfaller, M. A., Messer, S. A., Rhomberg, P. R., Borroto-Esoda, K., & Castanheira, M. (2017) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00161-17 · Cited by 84 · see citing works
Self-citation
Evaluation of the antifungal activity of the novel Oral Glucan synthase inhibitor SCY-078, singly and in combination, for the treatment of invasive aspergillosis
Ghannoum, M., Long, L., Larkin, E. L., Isham, N., Sherif, R., Borroto-Esoda, K., Barat, S., & Angulo, D. (2018) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00244-18 · Cited by 80 · see citing works
Self-citation
Activity of Isavuconazole and Other Azoles against Candida Clinical Isolates and Yeast Model Systems with Known Azole Resistance Mechanisms
Sanglard, D., & Coste, A. T. (2015) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02157-15 · Cited by 78 · see citing works
Discovery of a Novel Class of Orally Active Antifungal β-1,3- <scp>d</scp> -Glucan Synthase Inhibitors
Walker, S. S., Xu, Y., Triantafyllou, I., Waldman, M. F., Mendrick, C., Brown, N., Mann, P., Chau, A., Patel, R., Bauman, N., et al. (2011) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00432-11 · Cited by 75 · see citing works
In Vitro Activity of Ibrexafungerp (SCY-078) against Candida auris Isolates as Determined by EUCAST Methodology and Comparison with Activity against C. albicans and C. glabrata and with the Activities of Six Comparator Agents
Arendrup, M. C., Jørgensen, K. M., Hare, R. K., & Chowdhary, A. (2019) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02136-19 · Cited by 71 · see citing works
Antifungal Activity of SCY-078 and Standard Antifungal Agents against 178 Clinical Isolates of Resistant and Susceptible Candida Species
Schell, W. A., Jones, A. M., Borroto-Esoda, K., & Alexander, B. D. (2017) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01102-17 · Cited by 66 · see citing works
Self-citation
In Vitro Activity of Ibrexafungerp, a Novel Glucan Synthase Inhibitor against Candida glabrata Isolates with FKS Mutations
Nunnally, N. S., Etienne, K. A., Angulo, D., Lockhart, S. R., & Berkow, E. L. (2019) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01692-19 · Cited by 66 · see citing works
Self-citation
Gain-of-Function Mutations in PDR1 , a Regulator of Antifungal Drug Resistance in Candida glabrata, Control Adherence to Host Cells
Vale-Silva, L., Ischer, F., Leibundgut-Landmann, S., & Sanglard, D. (2013) · Infection and Immunity · doi:10.1128/iai.00074-13 · Cited by 65 · see citing works
Cost of invasive fungal infections in the era of new diagnostics and expanded treatment options
Ashley, E. D., Drew, R., Johnson, M., Danna, R., Dabrowski, D., Walker, V., Prasad, M., Alexander, B., Papadopoulos, G., & Perfect, J. (2012) · Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/j.1875-9114.2012.01124 · Cited by 62 · see citing works
Distribution of Candida species in women with vulvovaginal symptoms and their association with different ages and contraceptive methods
Çetin, M., Ocak, S., Güngören, A., & Hakverdi, A. U. (2007) · Scandinavian Journal of Infectious Diseases · doi:10.1080/00365540601148491 · Cited by 62 · see citing works
A Novel 1,3-Beta- d -Glucan Inhibitor, Ibrexafungerp (Formerly SCY-078), Shows Potent Activity in the Lower pH Environment of Vulvovaginitis
Larkin, E. L., Long, L., Isham, N. C., Borroto–Esoda, K., Barat, S., Angulo, D., Wring, S., & Ghannoum, M. A. (2019) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02611-18 · Cited by 52 · see citing works
Self-citation
Candidemia surveillance in Iowa: emergence of echinocandin resistance
Matsumoto, E., Boyken, L., Tendolkar, S., McDanel, J., Castanheira, M., Pfaller, M., & Diekema, D. (2014) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/j.diagmicrobio.2014.02.016 · Cited by 50 · see citing works
Isavuconazole and Nine Comparator Antifungal Susceptibility Profiles for Common and Uncommon Candida Species Collected in 2012: Application of New CLSI Clinical Breakpoints and Epidemiological Cutoff Values
Castanheira, M., Messer, S. A., Rhomberg, P. R., Dietrich, R. D., Jones, R. N., & Pfaller, M. A. (2014) · Mycopathologia · doi:10.1007/s11046-014-9772-2 · Cited by 46 · see citing works
Oral Ibrexafungerp: An Investigational Agent for the Treatment of Vulvovaginal Candidiasis
Azie, N., Angulo, D., Dehn, B., & Sobel, J. D. (2020) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2020.1791820 · Cited by 46 · see citing works
Self-citation
Clinical Pharmacokinetics and Drug‐Drug Interaction Potential for Coadministered SCY‐078, an Oral Fungicidal Glucan Synthase Inhibitor, and Tacrolimus
Wring, S. A., Murphy, G. M., Atiee, G. J., Corr, C., Hyman, M., Willett, M. S., & Angulo, D. A. (2018) · Clinical Pharmacology in Drug Development · doi:10.1002/cpdd.588 · Cited by 45 · see citing works
Self-citation
SCY-078, a Novel Fungicidal Agent, Demonstrates Distribution to Tissues Associated with Fungal Infections during Mass Balance Studies with Intravenous and Oral [ 14 C]SCY-078 in Albino and Pigmented Rats
Wring, S. A., Borroto–Esoda, K., Solon, E. G., & Angulo, D. A. (2018) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02119-18 · Cited by 45 · see citing works
Self-citation
The novel oral glucan synthase inhibitor SCY-078 shows in vitro activity against sessile and planktonic Candida spp
Marcos-Zambrano, L. J., Gómez-Perosanz, M., Escribano, P., Bouza, E., & Guinea, J. (2017) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkx010 · Cited by 44 · see citing works
Oral glucan synthase inhibitor SCY-078 is effective in an experimental murine model of invasive candidiasis caused by WT and echinocandin-resistant Candida glabrata
Wiederhold, N. P., Najvar, L. K., Jaramillo, R., Olivo, M., Pizzini, J., Catano, G., & Patterson, T. F. (2018) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkx422 · Cited by 43 · see citing works
Efficacy of Ibrexafungerp (SCY-078) against Candida auris in an In Vivo Guinea Pig Cutaneous Infection Model
Ghannoum, M. A., Isham, N. C., Angulo, D., Borroto–Esoda, K., Barat, S., & Long, L. (2020) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00854-20 · Cited by 41 · see citing works
Self-citation
Lack of Impact by SCY‐078, a First‐in‐Class Oral Fungicidal Glucan Synthase Inhibitor, on the Pharmacokinetics of Rosiglitazone, a Substrate for CYP450 2C8, Supports the Low Risk for Clinically Relevant Metabolic Drug‐Drug Interactions
Wring, S. A., Murphy, G. M., Atiee, G. J., Corr, C., Hyman, M., Willett, M. S., & Angulo, D. A. (2018) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.1146 · Cited by 39 · see citing works
Self-citation
Candida glabratasepsis secondary to oral colonization in bone marrow transplantation
Redding, S. W., Marr, K. A., Kirkpatrick, W. R., Coco, B. J., & Patterson, T. F. (2004) · Medical Mycology · doi:10.1080/13693780410001731574 · Cited by 38 · see citing works
Emergence of multiple resistance profiles involving azoles, echinocandins and amphotericin B in Candida glabrata isolates from a neutropenia patient with prolonged fungaemia
Cho, E., Shin, J. H., Kim, S. H., Kim, H., Park, J. S., Sung, H., Kim, M., & Im, H. J. (2014) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dku518 · Cited by 36 · see citing works
Synthesis and biological evaluation of antifungal derivatives of enfumafungin as orally bioavailable inhibitors of β-1,3-glucan synthase
Heasley, B. H., Pacofsky, G. J., Mamai, A., Liu, H., Nelson, K., Coti, G., Peel, M. R., Balkovec, J. M., Greenlee, M. L., Liberator, P., et al. (2012) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2012.05.031 · Cited by 35 · see citing works
Activity of a Novel 1,3-Beta- d -Glucan Synthase Inhibitor, Ibrexafungerp (Formerly SCY-078), against Candida glabrata
Ghannoum, M. A., Long, L., Isham, N. C., Hager, C. L., Wilson, R. A., Borroto–Esoda, K., Barat, S., & Angulo, D. (2019) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01510-19 · Cited by 31 · see citing works
Self-citation
Vaginal allergic response in women with vulvovaginal candidiasis
Fan, S., Liao, Q., Liu, X. P., Liu, Z., & Zhang, D. (2008) · International Journal of Gynecology & Obstetrics · doi:10.1016/j.ijgo.2007.08.024 · Cited by 26 · see citing works
Penetration of Ibrexafungerp (Formerly SCY-078) at the Site of Infection in an Intra-abdominal Candidiasis Mouse Model
Lee, A., Prideaux, B., Zimmerman, M., Carter, C. L., Barat, S., Angulo, D. A., Dartois, V. A., Perlin, D. S., & Zhao, Y. (2019) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02268-19 · Cited by 26 · see citing works
Self-citation
Candida colonization of the vagina in elderly residents of a long-term-care hospital
Dan, M., Segal, R., Marder, V. J., & Leibovitz, A. (2006) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/s10096-006-0150-y · Cited by 25 · see citing works
733. Ibrexafungerp Demonstrates Potent and Consistent In Vitro Activity Against >400 Global Candida auris Isolates, Including isolates with Elevated MIC’s to Echinocandins
Borroto–Esoda, K., Angulo, D. A., & Azie, N. E. (2020) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofaa439.925 · Cited by 6 · see citing works
Self-citation
SCY-078, a novel IV/oral triterpenoid anti-fungal treatment in development for vulvovaginal candidiasis and other severe invasive fungal infections, is not embryo/feto-toxic
Carruthers, C., Barat, S., Thomas, P., & Lewis, E. (2018) · American Journal of Obstetrics and Gynecology · doi:10.1016/j.ajog.2018.10.043 · Cited by 3 · see citing works

Flagged first, then by citations

Research works printed but not linked: 2

Barat S. Borroto-Esoda K. Angulo D. (Eds.) (2018). Ibrexafungerp (formerly SCY-078) Displays Potent In Vitro Activity Against C. glabrata Isolates with Mutations in fks Genes. (Lisbon, Portugal: European Society of Clinical Microbiology and Infectious Diseases/American Society Microbiology (ESCMID/ASM). Available at: https://d1io3yog0oux5.cloudfront.net/_98dd714dc33bcf17951bb234b5ca3d63/scynexis/db/385/2867/pdf/POSTER_Ibrexafungerp+%28formerly+SCY-078%29+Displays+Potent+In+Vitro+Activity+Against+C.+Glabrata+Isolates+with+Mutations+in+fks+Genes_ESCMID+ASM+2018.pdf.
Borroto-Esoda K. Birchall S. Moore C. B. Angulo D. (Eds.) (2017a). Assessment of the In Vitro Antifungal Activity of SCY-078 Against a Panel of Susceptible and Resistant, Clinical Candida Isolates from Europe. (New Orleans, LA: ASM). Available at: https://www.abstractsonline.com/pp8/#!/4358/presentation/6655.

Sorted by citations

The Antifungal Pipeline: Fosmanogepix, Ibrexafungerp, Olorofim, Opelconazole, and Rezafungin
Hoenigl, M., Sprute, R., Egger, M., Arastehfar, A., Cornely, O. A., Krause, R., Lass-Flörl, C., Prattes, J., Spec, A., Thompson, G. R., et al. (2021) · Drugs · doi:10.1007/s40265-021-01611-0 · Cited by 467 · see citing works
Candidemia: Evolution of Drug Resistance and Novel Therapeutic Approaches
Tortorano, A. M., Prigitano, A., Morroni, G., Brescini, L., & Barchiesi, F. (2021) · Infection and Drug Resistance · doi:10.2147/idr.s274872 · Cited by 96 · see citing works
Treatment of Vulvovaginal Candidiasis—An Overview of Guidelines and the Latest Treatment Methods
Satora, M., Grunwald, A., Zaremba, B., Frankowska, K., Żak, K., Tarkowski, R., & Kułak, K. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12165376 · Cited by 84 · see citing works
Management of recurrent vulvovaginal candidosis: Narrative review of the literature and European expert panel opinion
Donders, G., Sziller, I. O., Paavonen, J., Hay, P., de Seta, F., Bohbot, J. M., Kotarski, J., Vives, J. A., Szabo, B., Cepuliené, R., et al. (2022) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2022.934353 · Cited by 82 · see citing works
Ibrexafungerp: First Approval
Lee, A. (2021) · Drugs · doi:10.1007/s40265-021-01571-5 · Cited by 59 · see citing works
Clinical challenges in diagnosis and treatment of recurrent vulvovaginal candidiasis
Neal, C. M., & Martens, M. G. (2022) · SAGE Open Medicine · doi:10.1177/20503121221115201 · Cited by 56 · see citing works
New drug approvals for 2021: Synthesis and clinical applications
Yuan, S., Wang, D.-S., Liu, H., Zhang, S., Yang, W., Lv, M., Zhou, Y., Zhang, S., Song, J. H., & Liu, H. (2022) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2022.114898 · Cited by 51 · see citing works
Ibrexafungerp for the Treatment of Vulvovaginal Candidiasis: Design, Development and Place in Therapy
Phillips, N. A., Rocktashel, M., & Merjanian, L. (2023) · Drug Design Development and Therapy · doi:10.2147/dddt.s339349 · Cited by 54 · see citing works
Invasive candidiasis: investigational drugs in the clinical development pipeline and mechanisms of action
Hoenigl, M., Sprute, R., Arastehfar, A. A., Perfect, J. R., Lass‐Flörl, C., Bellmann, R., Prattes, J., Thompson, G. R., Wiederhold, N. P., Al‐Obaidi, M. M., et al. (2022) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2022.2086120 · Cited by 46 · see citing works
In Vitro Antifungal Activity of Ibrexafungerp (SCY-078) Against Contemporary Blood Isolates From Medically Relevant Species of Candida: A European Study
Quindós, G., Miranda-Cadena, K., San-Millán, R., Borroto–Esoda, K., Cantón, E., Linares-Sicilia, M. J., Hamprecht, A. G., Montesinos, I., Tortorano, A. M., Prigitano, A., et al. (2022) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2022.906563 · Cited by 41 · see citing works
Self-citation
Prevalence, antifungal susceptibility and etiology of vulvovaginal candidiasis in sub–Saharan Africa: a systematic review with meta-analysis and meta-regression
Mushi, M. F., Olum, R., & Bongomin, F. (2022) · Medical Mycology · doi:10.1093/mmy/myac037 · Cited by 37 · see citing works
Fungal cell wall biogenesis: structural complexity, regulation and inhibition
Gow, N. A. R. (2025) · Fungal Genetics and Biology · doi:10.1016/j.fgb.2025.103991 · Cited by 39 · see citing works
Vulvovaginal candidiasis-an overview of current trends and the latest treatment strategies
Bhosale, V. B., Koparde, A. A., & Thorat, V. M. (2025) · Microbial Pathogenesis · doi:10.1016/j.micpath.2025.107359 · Cited by 37 · see citing works
Pharmacokinetics and Pharmacodynamics of Ibrexafungerp
McCarthy, M. W. (2022) · Drugs in R&D · doi:10.1007/s40268-021-00376-x · Cited by 28 · see citing works
Targeting Fks1 proteins for novel antifungal drug discovery
Kumar, V., Huang, J., Dong, Y., & Hao, G. (2024) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2024.02.007 · Cited by 29 · see citing works
Molecular association of Candida albicans and vulvovaginal candidiasis: focusing on a solution
David, H., & Solomon, A. P. (2023) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2023.1245808 · Cited by 29 · see citing works
In Vitro pH Activity of Ibrexafungerp against Fluconazole-Susceptible and -Resistant Candida Isolates from Women with Vulvovaginal Candidiasis
Sobel, J. D., Borroto–Esoda, K., Azie, N. E., & Angulo, D. A. (2021) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00562-21 · Cited by 26 · see citing works
Self-citation
Emerging Diagnostics and Therapeutics for Invasive Fungal Infections
Friedman, D. Z. P., & Schwartz, I. S. (2023) · Infectious Disease Clinics of North America · doi:10.1016/j.idc.2023.05.001 · Cited by 23 · see citing works
Antifungal pipeline: New tools for the treatment of mycoses
Wolfgruber, S., Salmanton‐García, J., Kuate, M. P. N., Hoenigl, M., & Brunelli, J. G. P. (2024) · Revista Iberoamericana de Micología · doi:10.1016/j.riam.2024.11.001 · Cited by 26 · see citing works
Scaling up for success: from bioactive natural products to new medicines
Helf, M. J., Buntin, K., Klančar, A., Rust, M., Petersen, F., Pistorius, D., Weber, E., Wong, J., & Krastel, P. (2024) · Natural Product Reports · doi:10.1039/d4np00022f · Cited by 21 · see citing works
Ibrexafungerp: A new triterpenoid antifungal
Sucher, A. J., Thai, A., Tran, C., Mantena, N., Noronha, A., & Chahine, E. B. (2022) · American Journal of Health-System Pharmacy · doi:10.1093/ajhp/zxac256 · Cited by 21 · see citing works
Screening of the Pandemic Response Box Reveals an Association between Antifungal Effects of MMV1593537 and the Cell Wall of Cryptococcus neoformans , Cryptococcus deuterogattii , and Candida auris
de Oliveira, H. C., Castelli, R. F., Reis, F. C. G., Samby, K., Nosanchuk, J. D., Alves, L. R., & Rodrigues, M. L. (2022) · Microbiology Spectrum · doi:10.1128/spectrum.00601-22 · Cited by 21 · see citing works
Fluconazole-Resistant Candida albicans Vaginal Infections at a Referral Center and Treated With Boric Acid
File, B., Sobel, R., Becker, M., & Nyirjesy, P. (2023) · Journal of Lower Genital Tract Disease · doi:10.1097/lgt.0000000000000733 · Cited by 20 · see citing works
Beyond ergosterol: Strategies for combatting antifungal resistance in Aspergillus fumigatus and Candida auris
Cruz, R., & Wuest, W. M. (2023) · Tetrahedron · doi:10.1016/j.tet.2023.133268 · Cited by 19 · see citing works
The Feasibility of Ibrexafungerp for the Treatment of Fungal Infections in Patients with Hematological Malignancies
Daraškevičius, J., Petraitis, V., Davainis, L., & Žučenka, A. (2022) · Journal of Fungi · doi:10.3390/jof8050440 · Cited by 10 · see citing works
Genomic Assembly of Clinical Candida glabrata (Nakaseomyces glabrata) Isolates Reveals within-Species Structural Plasticity and Association with In Vitro Antifungal Susceptibility
Stefanini, I., Stoakes, E., Wu, H. H. T., Xu-McCrae, L., Hussain, A., Moat, J., Dowson, C. G., David, M. D., & Constantinidou, C. (2022) · Microbiology Spectrum · doi:10.1128/spectrum.01827-22 · Cited by 10 · see citing works
New Technologies to Diagnose and Treat a Multidrug-Resistant Candida auris: A Patent Review
Rossato, L. L., Simionatto, S., Serafini, M. R., & Alves, I. A. (2022) · Mycopathologia · doi:10.1007/s11046-022-00669-y · Cited by 9 · see citing works
Management of invasive candidiasis: A focus on rezafungin, ibrexafungerp, and fosmanogepix
August, B., & Kale-Pradhan, P. B. (2024) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.2926 · Cited by 8 · see citing works
New pharmacotherapeutic strategies for drug-resistant Candida infections: a review
Raposa, J., & Vázquez, J. A. (2024) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2024.2433605 · Cited by 8 · see citing works
Structural-guided identification of two modulators of β−1,3-glucan synthase FKS1
Li, J., Li, J., Zhu, A., Dai, X., Liu, J., Liu, H., Xia, Z., Dong, Y., Qian, W.-Y., Dai, L., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-67293-4 · Cited by 6 · see citing works
Antifungal susceptibility and biofilm production of Candida species– causative agents of female genital tract infections
Ranđelović, M., Dimitrijević, M., Mijatović, S., Ignjatović, A., Arsić-Arsenijević, V. S., Stojanović-Radić, Z. Z., Hay, R. J., & Otašević, S. (2024) · Brazilian Journal of Microbiology · doi:10.1007/s42770-024-01529-1 · Cited by 6 · see citing works
TO MARKET, TO MARKET–2021: SMALL MOLECULES
Araujo, E., Bell, I. M., Burckle, A. J., Koester, D. C., Manning, J. R., Caldwell, R. D., Castanedo, G. M., Green, S. A., Zeng, M., Debien, L., et al. (2022) · Medicinal chemistry reviews · doi:10.1021/mc-2022-vol57.ch24 · Cited by 6 · see citing works
New and emerging drugs for the treatment of invasive fungal infections
Maves, R. C., & Fowler, M. N. (2025) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2025.2568547 · Cited by 5 · see citing works
Molecular Targeting and Novel Therapeutic Approaches against Fungal Infections
Kumar, A., Bansal, P., Katiyar, D., Prakash, G. K. S., & Rao, N. G. R. (2023) · Current Molecular Medicine · doi:10.2174/1566524023666230302123310 · Cited by 5 · see citing works
A review of the fernane-type triterpenoids as anti-fungal drugs
Liu, C., Zhang, L., Liu, S.-X., Lu, Y., Li, C., & Pei, Y. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1447450 · Cited by 5 · see citing works
Efficacy of Voriconazole, Isavuconazole, Fluconazole, and Anidulafungin in the Treatment of Emerging Candida auris Using an Immunocompromised Murine Model of Disseminated Candidiasis
Gamal, A., Long, L. A., Herrada, J., Aram, J. A., McCormick, T. S., & Ghannoum, M. A. (2021) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00549-21 · Cited by 5 · see citing works
Self-citation
In vitro Evaluation of Fungal Susceptibility and Inhibition of Virulence by Diosgenin
Costa, M. D. S., Silva, A. R., Araújo, J. S., Santos, A., Fonseca, V. J. A., Alencar, G. G., Moura, T. F., Gonçalves, S. A., Barbosa‐Filho, J. M., Morais‐Braga, M. F. B., et al. (2024) · Chemistry & Biodiversity · doi:10.1002/cbdv.202400444 · Cited by 5 · see citing works
Character Virulence Association Factors and Gene Mutation Mediating Multidrug Resistance Phenotypes in Candidozyma duobushaemulonii
Zhou, H., Yang, X., Zhou, Q., Hu, C., Xin, C., & Song, Z. (2025) · Mycopathologia · doi:10.1007/s11046-025-01008-7 · Cited by 4 · see citing works
Current and emerging therapies for fungal biofilms and systemic infections
Elgammal, Y., Martinez, R. I. G., Requejo, A., & Martinez, L. R. (2025) · Critical Reviews in Microbiology · doi:10.1080/1040841x.2025.2570185 · Cited by 4 · see citing works
Ibrexafungerp for the treatment of vulvovaginal candidiasis: A systematic review and meta-analysis of randomized placebo-controlled trials
Kow, C. S., Ramachandram, D. S., Hasan, S. S., & Thiruchelvam, K. (2025) · Journal de Mycologie Médicale · doi:10.1016/j.mycmed.2025.101534 · Cited by 4 · see citing works
Epidemiological Characterization of Clinical Fungal Isolates from Pauls Stradinš Clinical University Hospital, Latvia: A 4-Year Surveillance Report
Jain, N., Jansone, I., Obidenova, T., Sīmanis, R., Meisters, J., Straupmane, D., & Reinis, A. (2021) · Life · doi:10.3390/life11101002 · Cited by 4 · see citing works
Characterization of Yeast Isolated from the Gut Microbiota of Tunisian Children with Autism Spectrum Disorder
Chamtouri, M., Merghni, A., Miranda-Cadena, K., Sakly, N., Gaddour, N., Reyes‐Gavilán, C. G. D. L., Mastouri, M., Eraso, E., & Quindós, G. (2024) · Journal of Fungi · doi:10.3390/jof10110730 · Cited by 3 · see citing works
Current opinion on the potential role of liposomal amphotericin B in underexplored clinical scenarios
Angelini, J., Ferin, S., Martini, L., Flammini, S., Tascini, C., & Giuliano, S. (2026) · Clinical Microbiology Reviews · doi:10.1128/cmr.00228-25 · Cited by 2 · see citing works
The Upcoming Antifungal Drugs in Clinical Development for the Treatment of Invasive Candidiasis
Zubovskaia, A., & Vázquez, J. A. (2026) · Infection and Drug Resistance · doi:10.2147/idr.s547511 · Cited by 2 · see citing works
Candida auris: Microbiological Characteristics and Laboratory Diagnosis of the Hidden Pathogen
Servi, E. Y., & Uzun, M. (2022) · Mediterranean Journal of Infection Microbes and Antimicrobials · doi:10.4274/mjima.galenos.2022.2022.28 · Cited by 2 · see citing works
The structural language of fungal cell wall sugars in WHO priority fungi: the determinant of pathogenicity and the gateway to new therapies
Trentin, G., Martins‐Santana, L., Taborda, C. P., & Almeida, F. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1912476 · Cited by 1 · see citing works
Novel Antifungals for the Treatment of Vulvovaginal Candidiasis: Where Are We?
Gamal, A., authorship, T. A. H. C. E. T. T. W. A. S. F., Kadry, A., authorship, T. A. H. C. E. T. T. W. A. S. F., Elshaer, M. Y. S., & Ghannoum, M. A. (2022) · touchREVIEWS in Infectious Diseases · doi:10.17925/id.2022.1.1.16 · Cited by 1 · see citing works
Self-citation
Oteseconazole in recurrent vulvovaginal candidiasis: a profile of its use
Fung, S. S.-P., & Shirley, M. (2023) · Drugs & Therapy Perspectives · doi:10.1007/s40267-023-01008-x · Cited by 1 · see citing works
Validation Testing of Sabouraud Liquid Medium in Determining the Antifungal Activity of Newly Synthesized compounds by the Method of Two-fold Serial Dilutions
Новикова, В. В., Пулина, Н. А., Luzhanin, V. G., & Курбатов, Е. Р. (2022) · Drug development & registration · doi:10.33380/2305-2066-2022-11-4(1)-91-98
Antifúngicos: lo que tenemos, lo que tendremos, lo que queremos.
Martínez-Méndez, D., Bravo-Acosta, M., & Semprún-Hernández, N. (2023) · Investigación Clínica · doi:10.54817/ic.v64n4a11
Advances in Managing Infections in Lung Transplantation: A Review
Chakravorty, S., & Patel, A. (2024) · OBM Transplantation · doi:10.21926/obm.transplant.2402215
Emerging Therapeutic Approaches in Recurrent Vaginal Candidiasis: From Azoles to Probiotics
Bhatia, S., Balasubramaniam, D., & Selvarajah, K. (2025) · International Journal of Advanced Research in Science Communication and Technology · doi:10.48175/ijarsct-28380
Natural Product Drug Discovery: Progress and Prospects
Singh, V. P., Verma, R., & Srivastava, V. (2025) · Royal Society of Chemistry eBooks · doi:10.1039/9781837676989-00001
Evolving Epidemiology and Emerging Antifungal Resistance in Vulvovaginal Candidosis: Evidence from a Five-Year Survey
Tsiakalos, A., Papageorgiou, D., Pitiriga, V. C., Vogiatzi, C., Ziakas, P. D., Routsias, I., Dimitroulia, E., & Akinosoglou, K. (2026) · Pathogens · doi:10.3390/pathogens15050538
Potent and broad-spectrum anti-Candida activity of 6α-(3’-methoxy-4’-hydroxybenzoyl)-lup-20(29)-ene-3-one, a triterpenoid from Paullinia pinnata
Harley, B. K., Ben, I. O., Asamoah, T. D., Amengor, C. D. K., Kortei, N. K., Eghan, P., & Fleischer, T. C. (2026) · PLoS ONE · doi:10.1371/journal.pone.0350399
Green spectrofluorimetric determination of Ibrexafungerp using NBD-Cl derivatization
Kamaly, O. M. A., & Sayedahmed, M. (2026) · Scientific Reports · doi:10.1038/s41598-026-59227-x
Fungal Esophagitis: Molecular Insights Into Pathogenesis and Emerging Antifungal Strategies
Papantoniou, K., Pastras, P., Aggeletopoulou, I., & Triantos, C. K. (2026) · Frontiers in Bioscience-Landmark · doi:10.31083/fbl50241
Elevated in vitro activity of ibrexafungerp against azole-resistant Candida isolates from Vulvovaginal Candidiasis (VVC): a multicentric study from India
Lather, P., Tilak, R., Mahor, A., Khuraijam, R., Bagga, R., Saha, P. K., Rudramurthy, S. M., Reddy, S., Verma, S., Kumari, S., et al. (2026) · Archives of Microbiology · doi:10.1007/s00203-026-05234-5

Ibrexafungerp: A First-in-Class Oral Triterpenoid Glucan Synthase Inhibitor
Jallow, S., & Govender, N. P. (2021) · Journal of Fungi · doi:10.3390/jof7030163 · Cited by 129 · see citing works
An evaluation of ibrexafungerp for the treatment of invasive candidiasis: the evidence to date
Colombo, R. E., & Vázquez, J. A. (2021) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2021.1890026 · Cited by 14 · see citing works
Ibrexafungerp: A Novel Oral Triterpenoid Antifungal in Development for the Treatment of Candida auris Infections
Ghannoum, M. A., Arendrup, M. C., Chaturvedi, V. P., Lockhart, S. R., McCormick, T. S., Chaturvedi, S., Berkow, E. L., Juneja, D., Tarai, B., Azie, N. E., et al. (2020) · Antibiotics · doi:10.3390/antibiotics9090539 · Cited by 92 · see citing works
Self-citation
Ibrexafungerp: A novel oral glucan synthase inhibitor
Davis, M. R., Donnelley, M. A., & Thompson, G. R. (2020) · Medical Mycology · doi:10.1093/mmy/myz083 · Cited by 91 · see citing works
In Vitro Activity of Ibrexafungerp, a Novel Glucan Synthase Inhibitor against Candida glabrata Isolates with FKS Mutations
Nunnally, N. S., Etienne, K. A., Angulo, D., Lockhart, S. R., & Berkow, E. L. (2019) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01692-19 · Cited by 66 · see citing works
Self-citation

Authors: Gamal, A., Chu, S., McCormick, T. S., Borroto-Esoda, K., Angulo, D., & Ghannoum, M. A.
Affiliations: Case Western Reserve University (US)
Scynexis (United States) (US)
University Hospitals of Cleveland (US)
Corresponding author: Ghannoum, Mahmoud A.
ORCID: Gamal, Ahmed
Chu, Sherman
McCormick, Thomas S.
Ghannoum, Mahmoud A.
Venue: Frontiers in Cellular and Infection Microbiology
Publisher: Frontiers Media SA
Published: 2021-03-11
Volume: 11
Pages: 642358-642358
ISSN: 2235-2988 (ISSN-L)
DOI: 10.3389/fcimb.2021.642358
PMC: PMC8006402
OpenAlex: W3134830038
Cited by: 58
References: 72
Citations by year: 2026: 8 · 2025: 9 · 2024: 10 · 2023: 9 · 2022: 15 · 2021: 7
FWCI: 1.20
Type: journal article
Language: en
Open access: gold
doi.org
Licence: cc-by
creativecommons.org/licenses/by/4.0/ (vor)
Locations: Frontiers in Cellular and Infection Microbiology (publishedVersion, cc-by)
PubMed Central (publishedVersion, cc-by)
PubMed (publishedVersion)
DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders: National Institutes of Health
National Institute of Allergy and Infectious Diseases (R21AI143305)
Topics: Health Sciences › Medicine › Infectious Diseases › Antifungal resistance and susceptibility
Life Sciences › Agricultural and Biological Sciences › Ecology, Evolution, Behavior and Systematics › Fungal Plant Pathogen Control
Health Sciences › Medicine › Epidemiology › Fungal Infections and Studies
Keywords: ibrexafungerp, Candida glabrata, oral antifungal agents, triterpenoids, antifungal resistance, azole resistance, echinocandin resistance, vaginal candidiasis, candidiasis, immunocompromised patients
MeSH terms: Antifungal Agents, Glycosides, Humans, Microbial Sensitivity Tests, Triterpenes, Drug Resistance, Fungal, Candida glabrata

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Ibrexafungerp, a Novel Oral Triterpenoid Antifungal in Development: Overview of Antifungal Activity Against Candida glabrata

Abstract

Integrity signals

Claims the paper makes

Claims other papers make about this one

Self-check

Cites

Cited by

Related

Record

About these checks